Vaxcyte (PCVX) Other financing activities (2019 - 2026)

Vaxcyte (PCVX) has reported Other financing activities for 8 consecutive years, with $9.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 49.31% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 43.24% YoY), while the FY2025 annual figure was $13.0 million, down 52.09% from the prior year.
• Other financing activities improved to $9.0 million in Q1 2026 per PCVX's latest filing, from $3.4 million in the prior quarter.
• Across five years, Other financing activities topped out at $11.7 million in Q3 2024 and bottomed at $268000.0 in Q2 2022.
• Historically, Other financing activities has averaged $3.9 million across 5 years, with a median of $3.8 million in 2023.
• Annual changes were most pronounced in 2024 — Other financing activities soared 900.8% — and 2025, when it plunged 97.39%.
• Vaxcyte's Other financing activities stood at $5.4 million in 2022, then slipped by 23.67% to $4.1 million in 2023, then surged by 45.77% to $6.0 million in 2024, then plunged by 42.93% to $3.4 million in 2025, then surged by 164.48% to $9.0 million in 2026.
• Business Quant data shows PCVX's Other financing activities at $9.0 million in Q1 2026, $3.4 million in Q4 2025, and $306000.0 in Q3 2025.